Search research articles
Contact Us
Filters
Showing results (301-310 of 375) with videos related to
Page
of 38
Sort By:
Breast (Edinburgh, Scotland)
|
July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study
Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
The Oncologist
|
January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL study
Simona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
Journal of Oncology
|
July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i>: A Review of Secondary Prevention Guidelines
Boudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
Tumori
|
June 6, 2015
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence
Giuseppe Bogina, Gianluigi Lunardi, Francesca Coati, et al.
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
JAMA Network Open
|
September 23, 2022
Contraceptive Use in Premenopausal Women With Early Breast Cancer
Matteo Lambertini, Claudia Massarotti, Julie Havas, et al.
Journal of the National Cancer Institute
|
May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
Matteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
Cancer Treatment and Research Communications
|
September 1, 2024
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients
Francesca Parisi, Giuseppa De Luca, Manuela Mosconi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui, Alex Pearson, Javier Cortes, et al.
NPJ Breast Cancer
|
December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer
Emma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Page
of 38
Search research articles
Search
Showing results (301-310 of 375) with videos related to
Sort By:
Page
of 38
Breast (Edinburgh, Scotland)
|
July 23, 2024
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study
Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, et al.
The Oncologist
|
January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL study
Simona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
Journal of Oncology
|
July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i>: A Review of Secondary Prevention Guidelines
Boudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
Tumori
|
June 6, 2015
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence
Giuseppe Bogina, Gianluigi Lunardi, Francesca Coati, et al.
Journal of the National Cancer Institute
|
June 8, 2018
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini, Christine Campbell, José Bines, et al.
JAMA Network Open
|
September 23, 2022
Contraceptive Use in Premenopausal Women With Early Breast Cancer
Matteo Lambertini, Claudia Massarotti, Julie Havas, et al.
Journal of the National Cancer Institute
|
May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy
Matteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
Cancer Treatment and Research Communications
|
September 1, 2024
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients
Francesca Parisi, Giuseppa De Luca, Manuela Mosconi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Rina Hui, Alex Pearson, Javier Cortes, et al.
NPJ Breast Cancer
|
December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer
Emma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Page
of 38